Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0002042266 XXXXXXXX LIVE 3 Common Stock, $0.0001 par value per share 05/18/2026 false 0001228627 67577R102 Opus Genetics, Inc. 8 Davis Drive Suite 220 Durham NC 27713 Russell Kelley, Managing Dir. (919) 610-2064 Foundation Fighting Blindness RD Fund 223 S. West Street, Suite 900 Raleigh NC 27603 0002042266 N Foundation Fighting Blindness Retinal Degeneration Fund b OO N DE 0 3792171 0 3792171 3792171 N 4.66 CO OO Percent of class represented in Row (11) is based on 81,395,539 shares of common stock, $0.0001 par value per share (the "Common Stock") of Opus Genetics, Inc., a Delaware corporation (the "Issuer") outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 12, 2026. 0002042532 N Foundation Fighting Blindness, Inc. b OO N MD 0 3792171 0 3792171 3792171 N 4.66 CO Percent of class represented in Row (11) is based on 81,395,539 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2026. Common Stock, $0.0001 par value per share Opus Genetics, Inc. 8 Davis Drive Suite 220 Durham NC 27713 This Amendment No. 3 on Schedule 13D amends the statement on Schedule 13D, dated October 29, 2024, which was amended on Schedule 13D/A dated March 6, 2025 and December 11, 2025, which relates to the Common Stock of the Issuer, filed by the Reporting Persons. This Amendment No. 3 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result of selling shares of the Issuer's Common Stock on May 18, 2026. Upon the closing of this transaction contemplated, the Reporting Persons will cease to be the beneficial owner of more than five percent of the Issuer's Common Stock. Accordingly, the Reporting Persons expect that this will be the final amendment to their Schedule 13D and constitutes an "exit filing" to terminate the Reporting Persons' reporting obligations under Section 13(d) of the Exchange Act upon such closing. 3,792,171 - 4.66% 3,792,171 Reference is made to the Form 4 filed by the Reporting Persons on May 20, 2026 with the SEC pursuant to Section 16 of the Act and is available on the SEC's website at www.sec.gov. The information reported in the filings are expressly incorporated herein. Not Applicable. Exhibit 1 - Agreement and Plan of Merger, dated October 22, 2024, by an among Ocuphire Pharma, Inc., Orange Merger Sub I, Inc., Orange Merger Sub II, LLC, and Opus Genetics Inc. (incorporated by reference to Exhibit 2.1 of the Issuer's Current Report on Form 8-K filed with the SEC on October 22, 2024). Exhibit 2 - Certificate of Designations of the Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Issuer's Current Report on Form 8-K filed with the SEC on October 22, 2024). Exhibit 3 - Form of Lock-Up Agreement (included as Exhibit B to the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer's current report on Form 8-K as filed with the SEC on October 22, 2024 and incorporated herein by reference). Exhibit 4 - Form of Registration Rights Agreement (included as Exhibit F to the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer's current report on Form 8-K as filed with the SEC on October 22, 2024 and incorporated herein by reference). Exhibit 5 - Joint Filing Agreement by and between the Reporting Persons (incorporated by reference to Exhibit 5 to the Reporting Persons' Schedule 13D/A as filed with the SEC on May 6, 2025). Foundation Fighting Blindness Retinal Degeneration Fund /s/ Russell Kelley Russell Kelley, Managing Director 05/20/2026 Foundation Fighting Blindness, Inc. /s/ Jason Menzo Jason Menzo, Chief Executive Officer 05/20/2026